Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.49
C$0.01(0.67%)
At close: 4:00 PM EST
C$0.49
C$0.01(0.67%)
Day’s Range― - ―
52-Week RangeC$0.31 - C$0.94
Previous CloseN/A
Volume4.97K
Average Volume (3M)27.52K
Market Cap
C$23.92M
Enterprise ValueC$26.32M
Total Cash (Recent Filing)C$419.58K
Total Debt (Recent Filing)C$553.41K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Plant-based Biologics FocusMustGrow’s core focus on mustard-derived and plant-based crop protection aligns with long-term structural demand for sustainable agricultural inputs. This differentiated technology base supports regulatory and partner-led commercialization paths, enabling persistent market relevance as farms shift toward biologics over several years.
Prior Commercial TractionThe firm demonstrated the ability to generate multi-million dollar revenue in recent years, indicating product-market fit and distribution capability. That prior scale is a durable sign the business can commercialize products again if product mix and cost structure improve, reducing execution uncertainty long term.
Moderate LeverageLeverage appears moderate versus equity, which provides some balance-sheet flexibility during continued operating losses. While equity has eroded, the absence of extreme debt levels supports ability to access financing or weather near-term cash burn without immediate solvency pressure, a durable financial buffer.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow materially depletes liquidity and forces dependence on external funding or asset sales. Over a multi-month horizon this constrains R&D, regulatory work and commercial rollout, increasing dilution or debt risk and making execution on long-term plans more uncertain.
Sharp Revenue Decline & VolatilityA large year-over-year revenue drop and volatile sales history reduce predictability of future cash flows and impair planning for regulatory and commercialization investments. This structural volatility signals market, competitive or execution weak points that could persist absent clear product or distribution fixes.
Deep Negative MarginsVery large negative operating and net margins indicate the current business model and cost base cannot sustainably convert revenue to profits. Persistent deep losses erode equity and limit internal funding for growth initiatives, raising structural questions about path to profitability without major strategy or cost changes.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.31 and its highest was C$0.94 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$23.92M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 37 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---